SHANGHAI, Sept. 17, 2015 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading open-access R&D capability
and technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, today announced that
it has been awarded the 2015 Frost & Sullivan North American
Open-Access R&D Technology Leadership Award. The award is part
of Frost & Sullivan's Growth, Innovation & Leadership Award
series, recognizing companies that have demonstrated excellence in
devising and implementing strong growth strategies.
WuXi was recognized for its outstanding achievement and strong
performance in helping its customers improve their R&D
productivity while reducing cost through a model of R&D
enablement. Together with over 2,000 partners worldwide, WuXi is
advancing breakthroughs in science and medicine that help people
around the world lead happier and healthier lives. Frost &
Sullivan views WuXi as an innovator in business relationships
across the entire pharmaceutical and biotechnology value
chain.
"We thank Frost & Sullivan for recognizing WuXi's diligent
efforts in building an open-access R&D enabling platform," said
Dr. Ge Li, chairman and CEO of WuXi
PharmaTech. "We also thank our customers and collaborative partners
for their trust and support in our journey. WuXi is honored to play
an important role in helping to bring better medicines to patients
faster."
About WuXi PharmaTech
WuXi PharmaTech is a research-driven and customer-focused
company, providing pharmaceutical, biotechnology, and medical
device companies with a broad and integrated portfolio of
laboratory and manufacturing services throughout the drug and
medical device R&D process. The company is also building a
platform to provide clinical diagnostic services directly to
physicians and their patients globally. WuXi's services are
designed to help its global partners in shortening the cycle and
lowering the cost of drug and medical device R&D. WuXi has the
first whole CMC platform in China
inspected by the U.S. FDA; the first cGMP biologics manufacturing
facility in China that is
compliant with U.S., European and Chinese regulatory standards; the
first GLP preclinical laboratory in China that is double certified with an OECD
country and CFDA; the first GLP/GCP bioanalytical laboratory in
China that has passed U.S. FDA,
OECD, and CFDA inspections; and the first CLIA-certified clinical
genomics lab in China. WuXi
PharmaTech's operating subsidiaries are known as WuXi
AppTec.
About Frost & Sullivan Growth, Innovation &
Leadership Awards
Frost & Sullivan Growth, Innovation & Leadership Awards
recognize companies in a variety of regional and global markets for
demonstrating outstanding achievement and superior performance in
areas such as leadership, technological innovation, customer
service, and strategic product development. Industry analysts
compare market participants and measure performance through
in-depth interviews, analysis, and extensive secondary research in
order to identify best practices in the industry. This research is
an invaluable source to companies for new ideas to improve
strategies and processes, which ultimately drive corporate growth.
These achievements are recognized at the Frost & Sullivan
Growth, Innovation & Leadership Awards Gala.
For more information, please contact:
WuXi PharmaTech
Ronald Aldridge (for investors)
LaVoieHealthScience
T: +1-617-374-8800 x109
M: +1 617-792-2459
ir@wuxiapptec.com
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
pr@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-receives-2015-open-access-rd-technology-leadership-award-from-frost--sullivan-300144084.html
SOURCE WuXi PharmaTech (Cayman) Inc.